Of the 10 analysts covering Alumis Inc., 1 rates it a strong buy, 8 rate it a buy and 1 rates it a hold. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
In its most recent quarterly report, Alumis Inc. posted a loss of $1.11 per share against an estimate of -$0.767, missing expectations by 44.72%. Upcoming reports are listed in the earnings calendar.
Alumis Inc. reported revenue of $1.66M in its most recent quarter, which has decreased by 37.66% compared with the same quarter a year earlier. Analysts had expected $3.65M.
Companies most comparable to Alumis Inc. include AnaptysBio, Inc., Odyssey Therapeutics, Inc., Rigel Pharmaceuticals, Inc., Aclaris Therapeutics, Inc. and Avalo Therapeutics, Inc.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Alumis Inc. shows a sell rating today and a sell rating on the weekly timeframe. Technical ratings are indicators, not investment advice.
This information is provided for general purposes only and is not investment advice.